|
1.
|
|
12 p, 1.1 MB |
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL : primary analysis of the CAPTIVATE FD cohort
/
Tam, Constantine S (University of Melbourne) ;
Allan, John N (Weill Cornell Medicine) ;
Siddiqi, Tanya (City of Hope National Medical Center) ;
Kipps, Thomas J. (University of California San Diego) ;
Jacobs, Ryan (Levine Cancer Institute) ;
Opat, Stephen (Monash University) ;
Barr, Paul M. (University of Rochester Medical Center) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Trentin, Livio (University of Padova) ;
Bannerji, Rajat (Rutgers Cancer Institute of New Jersey) ;
Jackson, Sharon (Middlemore Hospital) ;
Kuss, Bryone J. (Flinders University and Medical Center) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Szafer-Glusman, Edith (Pharmacyclics LLC. an AbbVie Company) ;
Russell, Kristin (Pharmacyclics LLC. an AbbVie Company) ;
Zhou, Cathy (Pharmacyclics LLC. an AbbVie Company) ;
Ninomoto, Joi (Pharmacyclics LLC. an AbbVie Company) ;
Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ;
Wierda, William G. (DepaUniversity of Texas MD Anderson Cancer Center) ;
Ghia, Paolo (IRCCS Ospedale San Raffaele) ;
Universitat Autònoma de Barcelona
CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort investigating fixed-duration (FD) treatment with ibrutinib plus venetoclax are reported. [...]
2022 -  10.1182/blood.2021014488
Blood, Vol. 139 Núm. 22 (february 2022) , p. 3278-3289
|
|
|
2.
|
|
9 p, 442.2 KB |
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
/
Woyach, Jennifer A. (The Ohio State University Comprehensive Cancer Center, Columbus, Ohio) ;
Ghia, Paolo (Universita Vita-Salute San Raffaele, Milan, Italy) ;
Byrd, John C. (University of Cincinnati College of Medicine, Cincinnati, Ohio) ;
Ahn, Inhye E. (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland) ;
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Brien, Susan M. (UC Irvine. Chao Family Comprehensive Cancer Center, Irvine, California) ;
Jones, Daniel (The Ohio State University Comprehensive Cancer Center, Irvine, California) ;
Cheung, Leo W.K. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Chong, Elizabeth (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Kwei, Kevin (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Dean, James P. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
James, Dannelle F. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Wiestner, Adrian (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland)
Purpose: Acquired mutations in Bruton's tyrosine kinase (BTK) or phospholipase C-γ2 (PLCG2) genes are associated with clinical progressive disease (PD) in patients with chronic lymphocytic leukemia (CLL) treated with BTK inhibitors. [...]
2023 - 10.1158/1078-0432.CCR-22-3887
Clinical Cancer Research, Vol. 29 Núm. 16 (august 2023) , p. 3065-3073
|
|
|
3.
|
|
10 p, 685.7 KB |
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia : the phase 2 CAPTIVATE study
/
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ;
Tam, Constantine S. (Monash University) ;
Grigg, Andrew (Austin Hospital) ;
Scarfò, Lydia (Università Vita Salute San Raffaele) ;
Kipps, Thomas J. (University of California. Moores Cancer Center) ;
Srinivasan, Srimathi (Janssen Research & Development) ;
Mali, Raghuveer Singh (Pharmacyclics LLC. an AbbVie Company) ;
Zhou, Cathy (Pharmacyclics LLC. an AbbVie Company) ;
Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ;
Szafer Glusman, Edith (Pharmacyclics LLC. an AbbVie Company) ;
Choi, Michael (University of California)
We evaluated immune cell subsets in patients with chronic lymphocytic leukemia (CLL) who received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax in the minimal residual disease (MRD) cohort of the CAPTIVATE study (NCT02910583). [...]
2023 - 10.1182/bloodadvances.2023010236
Blood advances, Vol. 7 Núm. 18 (26 2023) , p. 5294-5309
|
|
|
4.
|
|
16 p, 1.3 MB |
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma
/
Mar, Nataliya (University of California Irvine) ;
Zakharia, Yousef (University of Iowa Hospitals and Clinics) ;
Falcon, Alejandro (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Morales-Barrera, Rafael (Vall d'Hebron Institut d'Oncologia) ;
Mellado, Begona (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Duran, Ignacio (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Oh, Do-Youn (Seoul National University Hospital) ;
Williamson, Stephen K. (University of Kansas Hospital Cancer Center) ;
Gajate, Pablo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Arkenau, Hendrik-Tobias (University College London Cancer Institute) ;
Jones, Robert J. (BUniversity of Glasgow) ;
Teo, Min Yuen (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Turan, Tolga (Pharmacyclics (Estats Units d'Amèrica)) ;
McLaughlin, Robert T. (Pharmacyclics (Estats Units d'Amèrica)) ;
Peltier, Hillary M. (Pharmacyclics (Estats Units d'Amèrica)) ;
Chong, Elizabeth (Pharmacyclics (Estats Units d'Amèrica)) ;
Atluri, Harisha (Pharmacyclics (Estats Units d'Amèrica)) ;
Dean, James P. (Pharmacyclics (Estats Units d'Amèrica)) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Universitat Autònoma de Barcelona
Urothelial carcinoma (UC) is a common type of bladder cancer. Patients with UC that has not improved after previous treatment or has spread to other parts of the body need new treatment options. Ibrutinib is a drug approved for the treatment of blood cancers and chronic graft-versus-host disease. [...]
2023 - 10.3390/cancers15112978
Cancers, Vol. 15 (may 2023)
|
|
|
5.
|
|
7 p, 267.3 KB |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations : a pooled analysis from four clinical trials
/
Allan, John N. (Weill Cornell Medicine) ;
Shanafelt, Tait (Stanford University Medical Center) ;
Wiestner, Adrian (National Heart, Lung, and Blood Institute) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
O'Brien, Susan M. (University of California Irvine) ;
Li, Jianling (Pharmacyclics LLC) ;
Krigsfeld, Gabriel (Pharmacyclics LLC) ;
Dean, James P. (Pharmacyclics LLC) ;
Ahn, Inhye E. (National Heart, Lung, and Blood Institute) ;
Universitat Autònoma de Barcelona
TP53 aberrations [del(17p) or TP53 mutation] predict poor survival with chemoimmunotherapy in patients with chronic lymphocytic leukaemia (CLL). We evaluated long-term efficacy and safety of first-line ibrutinib-based therapy in patients with CLL bearing TP53 aberrations in a pooled analysis across four studies: PCYC-1122e, RESONATE-2 (PCYC-1115/16), iLLUMINATE (PCYC-1130) and ECOG-ACRIN E1912. [...]
2021 - 10.1111/bjh.17984
British Journal of Haematology, Vol. 196 (december 2021) , p. 947-953
|
|
|
6.
|
|
13 p, 1.6 MB |
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab : final analysis of the randomized, phase III iLLUMINATE trial
/
Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Greil, Richard (Salzburg Cancer Research Institute-CCCIT (Àustria)) ;
Demirkan, Fatih (Dokuz Eylul University (Turquía)) ;
Tedeschi, Alessandra (Niguarda Ca Granda Hospital (Itàlia)) ;
Anz, Bertrand (Tennessee Oncology (Estats Units)) ;
Larratt, Loree (University of Alberta Hospital (Canadà)) ;
Simkovic, Martin (University Hospital and Medical School Hradec (Txèquia)) ;
Novak, Jan (Charles University (Txèquia)) ;
Strugov, Vladimir (Almazov National Medical Research Centre (Rússia)) ;
Gill, Devinder (Princess Alexandra Hospital) ;
Gribben, John G. (Barts Cancer Institute) ;
Kwei, Kevin (Pharmacyclics LLC) ;
Dai, Sandra (Pharmacyclics LLC) ;
Hsu, Emily (Pharmacyclics LLC) ;
Dean, James P. (Pharmacyclics LLC) ;
Flinn, Ian W. (Sarah Cannon Research Institute) ;
Universitat Autònoma de Barcelona
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. [...]
2022 - 10.3324/haematol.2021.279012
Haematologica, Vol. 107 (january 2022) , p. 2108-2120
|
|
|
7.
|
|
15 p, 664.9 KB |
Ibrutinib plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia : Primary Analysis Results from the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
/
Wierda, W. G. (University of Texas.) ;
Allan, J. N. (Weill Cornell Medicine) ;
Siddiqi, Tanya (City of Hope National Medical Center) ;
Kipps, T. J. (UCSD. Moores Cancer Center) ;
Opat, S. (Monash University) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Badoux, X. C. (Ministry of Health) ;
Kuss, B. J. (Flinders University. Medical Centre) ;
Jackson, S. (Middlemore Hospital) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Jacobs, R. M. D. (Levine Cancer Institute) ;
Pagel, J. M. (Swedish Cancer Institute. Center for Blood Disorders and Stem Cell Transplantation) ;
Flinn, I. (Sarah Cannon Research Institute. Tennessee Oncology) ;
Pak, Y. (Pharmacyclics LLC. AbbVie Company) ;
Zhou, Cathy (Pharmacyclics LLC. AbbVie Company) ;
Szafer-Glusman, E. (Pharmacyclics LLC. AbbVie Company) ;
Ninomoto, J. (Pharmacyclics LLC. AbbVie Company) ;
Dean, James P (Pharmacyclics LLC. AbbVie Company) ;
James, D. F. (Pharmacyclics LLC. AbbVie Company) ;
Ghia, Paolo (Università Vita-Salute San Raffaele. IRCCS Ospedale San Raffaele) ;
Tam, C. S. (Peter MacCallum Cancer Center. St Vincent's Hospital. University of Melbourne) ;
Universitat Autònoma de Barcelona
PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). [...]
2021 - 10.1200/JCO.21.00807
Journal of Clinical Oncology, Vol. 39 Núm. 34 (january 2021) , p. 3853-3865
|
|
|
8.
|
|
12 p, 1.8 MB |
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study
/
Burger, Jan A. (University of Texas MD Anderson Cancer Center. Department of Leukemia) ;
Barr, Paul M. (Wilmot Cancer Institute, University of Rochester Medical Center) ;
Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital) ;
Owen, Carolyn (University of Calgary. Tom Baker Cancer Centre) ;
Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ;
Bairey, Osnat (Tel Aviv University. Rabin Medical Center, Petah Tikva, Israel and Sackler Faculty of Medicine) ;
Hillmen, Peter (University of Leeds. The Leeds Teaching Hospitals, St. James Institute of Oncology) ;
Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Center) ;
Devereux, Stephen (NHS Foundation Trust. Kings College Hospital) ;
Grosicki, Sebastian (Silesiam Medical University. Department of Hematology and Cancer Prevention) ;
McCarthy, Helen (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ;
Simpson, David (North Shore Hospital) ;
Offner, Fritz (Universitair Ziekenhuis Gent) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Dai, Sandra (Pharmacyclics LLC, an AbbVie Company) ;
Lal, Indu (Pharmacyclics LLC, an AbbVie Company) ;
Dean, James P. (Pharmacyclics LLC, an AbbVie Company) ;
Kipps, Thomas J. (UCSD Moores Cancer Center) ;
Universitat Autònoma de Barcelona
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0. [...]
2019 - 10.1038/s41375-019-0602-x
Leukemia, Vol. 34 (october 2019) , p. 787-798
|
|
|
9.
|
|
11 p, 1.8 MB |
Final analysis from RESONATE : Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
/
Munir, Talha (St. James's Hospital ( Dublín, Irlanda)) ;
Brown, J. R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
O'Brien, Susan (UC Irvine. Chao Family Comprehensive Cancer Center) ;
Barrientos, Jacqueline C. (Northwell Health Cancer Institute (Estats Units d'Amèrica)) ;
Barr, Paul M (Wilmot Cancer Institute. University of Rochester Medical Center) ;
Reddy, N. M. (Vanderbilt-Ingram Cancer Center) ;
Coutre, Steven E. (Stanford Cancer Center. Stanford University School of Medicine) ;
Tam, C. S. (Peter MacCallum Cancer Centre. St. Vincent's Hospital and University of Melbourne) ;
Mulligan, S. P. (Royal North Shore Hospital) ;
Jaeger, Ulrich (Division of Hematology and Hemostaseology. Medical University of Vienna) ;
Kipps, T. J. (UCSD Moores Cancer Center) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Montillo, M. (Niguarda Ca' Granda Hospital) ;
Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ;
Byrd, J. C. (The Ohio State University Comprehensive Cancer Center) ;
Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ;
Dai, Sandra (Pharmacyclics LLC. an AbbVie Company) ;
Szoke, A. (Pharmacyclics LLC. an AbbVie Company) ;
Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ;
Woyach, J. A. (The Ohio State University Comprehensive Cancer Center) ;
Universitat Autònoma de Barcelona
Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). [...]
2019 - 10.1002/ajh.25638
American Journal of Hematology, Vol. 94 Núm. 12 (january 2019) , p. 1353-1363
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
